Angion Biomedica Corp.

Angion (ANGN) Down on Merger Agreement With Private Biotech

New Strong Buy Stocks for November 16th

New Strong Buy Stocks for October 25th

Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why

What to Know About Buying Penny Stocks on June 1st

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021

Angion to Present Multiple Posters at Kidney Week 2021

Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis

Angion to Participate in Upcoming September Investment Conferences

Angion Biomedica Shares Moving Higher On Encouraging Results From Early Stage Trial Of Fibrotic Disease Candidate

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion Biomedica: Interesting New IPO With Late Stage Asset Targeting A Novel Indication

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia

Angion Announces Partial Waiver of Certain Lock-up Restrictions

ANGN Stock Price Increases Over 25% Pre-Market: Why It Happened